Core Insights - Biophytis SA announces new preclinical data supporting its investigational drug BIO101 aimed at restoring mobility in patients with obesity [1][5] - The combination of BIO101 with GLP-1 receptor agonists shows significant improvements in muscle strength and mobility in preclinical studies [2][7] Company Overview - Biophytis is a clinical-stage biotechnology company focused on developing treatments for age-related diseases, with its lead drug candidate BIO101 targeting muscular diseases and metabolic disorders [6] Research Findings - The preclinical study demonstrated that the combination treatment of BIO101 and GLP-1 significantly improved mobility and grip strength in diet-induced obese mice compared to untreated groups [2][3] - Previous early-phase clinical trials indicated that BIO101 improved muscle strength and mobility in obese patient cohorts compared to placebo [3] Health Context - Obesity is a global health crisis affecting nearly one billion people, with 96% of patients reporting a decline in muscle strength, which impacts mobility [4][7] - The CEO of Biophytis emphasized the need for therapies that restore muscle strength and mobility in obesity patients, highlighting the company's commitment to addressing this unmet medical need [5]
Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity